News

(Unaudited data)

QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)

Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Press release

Paris, December 6, 2021

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

• Quantum Genomics will receive up to $20 M

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON^® QuantiFERON^®-TB Gold Plus

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE MIB: DIA) gaben heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den LIAISON^® QuantiFERON^®-TB Gold

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die auf Polymerase-Kettenreaktionen (Polymerase Chain Reaction, PCR) basierenden Tests des Unternehmens auch

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the

Regulatory News:

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has secured a €4.3

Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health

Press release

Paris, November 25, 2021

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

• Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30%

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent

Press release

Paris, November 23, 2021

Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences

Quantum Genomics (Euronext Growth : ALQGC, OTCQX 

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.

William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial

Regulatory News:

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:

IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

ICON plc (NASDAQ:ICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the